Flu Shot Sales Increased

A leader in influenza prevention today announced significant growth in its vaccine business against a backdrop of reduced immunization rates worldwide.

CSL Seqirus confirmed that on August 15, 2023, its total revenue of $2,031 million was up 9%, driven by growth in seasonal influenza vaccines, particularly FLUCELVAX®, which increased 30%.

FLUCELVAX's indication now includes six months+ age indication in the U.S., Argentina, Canada, Taiwan, Australia & New Zealand.

Additionally, the U.S. Centers for Disease Control and Prevention (CDC) recognized FLUAD® as a preferentially recommended seasonal vaccine option for adults aged 65+ years.

Both of these vaccines for the 2023-2024 flu season began shipping globally, including the U.S., on July 17, 2023.

Dr. Gregg Sylvester, Chief Health Officer CSL Seqirus, commented in a related press release, "As we commence shipment to healthcare providers across the U.S., it's critical that we raise immunization rates this season to help protect as many people as possible from influenza and its potentially life-threatening complications."

The CDC encourages most people to get an annual flu shot before influenza viruses arrive. These vaccines are generally available at health clinics and community pharmacies in the U.S.